CD274 and familial pancreatic carcinoma: This study demonstrated that vaccine-based therapies may have adequately primed pancreatic cancer for anti-PD-1/PD-L1 treatments, highlighting that this typically T-cell-effector poor/Treg-rich tumor [61] could be potentially treated with PD-1/PD-L1 inhibitors.